Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Paresh Kumar

Goodwin Procter

main

Kumar Paresh

Goodwin Associate Paresh Kumar, from Boston, practices in the firm’s Technology and Life Sciences groups in the Intellectual Property Transactions and Strategies

Paresh Kumar

Experience

Areas of Practice

Professional Activities

Credentials

Education

JD2018

Pharm.D.2014

BSPharmacy2013

Admissions

Bars

Related Content

Martin Gomez, Paresh Kumar, and Morgan Monroe to Participate in 2023 Leadership Council on Legal Diversity Programs

Envisagenics Signs Research Collaboration with Bristol Myers Squibb

Acadia Pharmaceuticals and Stoke Therapeutics Announce Collaboration for $60 Million Upfront and up to $907 Million in Milestones and Royalties

Concert Pharmaceuticals Announces $65 Million Financing

Trillium Therapeutics to be Acquired by Pfizer for $2.26 Billion

Exicure Collaborates with Ipsen on Treatment For Rare Neurodegenerative Disorders, Exicure to Receive $20 Million Upfront and Up to $1 Billion in Milestone Payments

Centessa Completes $379.5 Million Initial Public Offering

Life Sciences

Intellectual Property

Litigation